Edition:
United States

Sol Gel Technologies Ltd (SLGL.OQ)

SLGL.OQ on NASDAQ Stock Exchange Global Market

6.99USD
18 Apr 2019
Change (% chg)

$-0.14 (-1.96%)
Prev Close
$7.13
Open
$7.03
Day's High
$7.14
Day's Low
$6.99
Volume
9,833
Avg. Vol
4,336
52-wk High
$10.00
52-wk Low
$5.61

Latest Key Developments (Source: Significant Developments)

Sol Gel Technologies Ltd Files For Mixed Shelf Of Up To $120 Million
Thursday, 28 Mar 2019 01:47pm EDT 

March 28 (Reuters) - Sol Gel Technologies Ltd ::SOL GEL TECHNOLOGIES LTD FILES FOR MIXED SHELF OF UP TO $120 MILLION – SEC FILING.  Full Article

Sol Gel Reports $63 Mln In Cash And Cash Equivalents, Deposits And Marketable Securities
Thursday, 21 Mar 2019 04:06pm EDT 

March 21 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.SOL GEL TECHNOLOGIES LTD - AS OF DECEMBER 31, 2018 HAD $63.0 MILLION IN CASH AND CASH EQUIVALENTS, DEPOSITS AND MARKETABLE SECURITIES.  Full Article

Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Zovirax Cream 5 Pct
Wednesday, 6 Feb 2019 08:45am EST 

Feb 6 (Reuters) - Perrigo Company PLC ::PERRIGO ANNOUNCES FDA FINAL APPROVAL FOR ITS AB RATED GENERIC VERSION OF ZOVIRAX® CREAM 5%.PERRIGO COMPANY PLC - COMPANY ANTICIPATES LAUNCHING GENERIC VERSION OF ZOVIRAX CREAM 5% THIS MONTH..  Full Article

Sol-Gel Technologies announces sixth agreement for a generic product candidate with Perrigo
Tuesday, 4 Dec 2018 04:05pm EST 

Dec 4 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES ANNOUNCES SIXTH AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES - ENTERED INTO SIXTH COLLABORATIVE AGREEMENT WITH PERRIGO ISRAEL FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF GENERIC PRODUCT CANDIDATE.  Full Article

Sol-Gel Technologies Ltd - Additional Collaborative Agreement With Perrigo
Thursday, 1 Nov 2018 04:05pm EDT 

Nov 1 (Reuters) - Perrigo Company PLC ::SOL GEL TECHNOLOGIES LTD - ADDITIONAL COLLABORATIVE AGREEMENT FOR A GENERIC PRODUCT CANDIDATE WITH PERRIGO.SOL GEL TECHNOLOGIES LTD - PERRIGO WILL SEEK REGULATORY APPROVAL WITH FDA FOR GENERIC PRODUCT CANDIDATE.  Full Article

Sol-Gel Technologies Qtrly Loss Per Share $0.36
Wednesday, 8 Aug 2018 07:05am EDT 

Aug 8 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.SOL GEL TECHNOLOGIES LTD - QTRLY LOSS PER SHARE $0.36.SOL GEL TECHNOLOGIES LTD - PLANS TO COMMENCE A BIOEQUIVALENCE STUDY FOR A GENERIC PRODUCT CANDIDATE IN Q4 OF 2018.SOL GEL TECHNOLOGIES LTD - EXPECTS TO REPORT TOP-LINE DATA FROM PIVOTAL PHASE III CLINICAL PROGRAM FOR EPSOLAY AND TWIN IN 2019.  Full Article

Sol-Gel Technologies Reports Q4 Loss Of $5.5 Mln Vs. Loss Of $4.9 Mln A Year Earlier
Monday, 26 Mar 2018 07:05am EDT 

March 26 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.SOL GEL TECHNOLOGIES LTD - AS OF DECEMBER 31, 2017, SOL-GEL HAD $5.0 MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $7.0 MILLION AS OF DECEMBER 31, 2016.SOL GEL TECHNOLOGIES - LOSS OF $5.5 MILLION FOR THE FOURTH QUARTER OF 2017, COMPARED TO A LOSS OF $4.9 MILLION FOR THE SAME PERIOD IN 2016.  Full Article